Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Stem Cell Research and Therapy is Scopus-indexed (Q1, CiteScore 11.9), WoS SCIE, DOAJ. It is covered by India's One Nation One Subscription scheme, which pays the article processing charge for authors at eligible institutions. Published by BioMed Central Ltd.
Checked against the index lists dated .
ISSN 1757-6512Verify ISSN ↗
Publisher: BioMed Central Ltd
Cost to publish: APC covered for authors at ONOS-subscribed Indian institutions
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Biochemistry, Genetics and Molecular Biology (miscellaneous) | 8 / 144 | 94th | Q1 |
| Medicine (miscellaneous) | 34 / 466 | 92nd | Q1 |
| Molecular Medicine | 21 / 179 | 88th | Q1 |
| Cell Biology | 47 / 289 | 83rd | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription)
Yes — actively indexed in Scopus, coverage 2010–present, best quartile Q1, CiteScore 11.9.
Stem Cell Research and Therapy is Q1 in Biochemistry, Genetics and Molecular Biology (miscellaneous) (rank 8 of 144), Q1 in Medicine (miscellaneous) (rank 34 of 466) and Q1 in Molecular Medicine (rank 21 of 179), by CiteScore 2025. It is ranked in 4 subject areas in all.
Stem Cell Research and Therapy is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 11.9, which places it in quartile Q1 at the 94th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.939, quartile Q1, with an H-index of 150.
For authors at Indian institutions covered by One Nation One Subscription (ONOS), the article processing charge is paid by the scheme. The publisher lists an article processing charge of about US$3,190 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Stem Cell Research and Therapy is published by BioMed Central Ltd. Its ISSN is 1757-6512.
Yes. ONOS also covers its article processing charge for authors at eligible institutions.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Stem Cell Research and Therapy has an h-index of 181 and a 2-year mean of 7.43 citations per paper (OpenAlex). Its Scopus CiteScore is 11.9, quartile Q1. On 2-year citations it ranks #8 of 141 Scopus journals in Biochemistry, Genetics and Molecular Biology (miscellaneous).
Stem Cell Research and Therapy published 763 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2026), authors are most often from China (44.2%), Japan (9.3%) and South Korea (8.2%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 82 retracted papers are recorded (14.3 per 1,000 papers). The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.